Indian Journal of Ophthalmology

LETTER TO THE EDITOR
Year
: 2014  |  Volume : 62  |  Issue : 1  |  Page : 97-

Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy


Jay Kumar Chhablani, Ritesh Narula, Raja Narayanan 
 Smt. Kanuri Santhamma Retina Vitreous Service, LV Prasad Eye Institute, Kallam Anji Reddy Campus, Banjara Hills, Hyderabad - 500 034, Andhra Pradesh, India

Correspondence Address:
Raja Narayanan
Smt. Kanuri Santhamma Retina Vitreous Service, LV Prasad Eye Institute, Kallam Anji Reddy Campus, Banjara Hills, Hyderabad - 500 034, Andhra Pradesh
India




How to cite this article:
Chhablani JK, Narula R, Narayanan R. Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy.Indian J Ophthalmol 2014;62:97-97


How to cite this URL:
Chhablani JK, Narula R, Narayanan R. Intravitreal bevacizumab monotherapy for treatment-naive polypoidal choroidal vasculopathy. Indian J Ophthalmol [serial online] 2014 [cited 2020 Sep 19 ];62:97-97
Available from: http://www.ijo.in/text.asp?2014/62/1/97/126197


Full Text

Dear Editor,

We thank the authors for their comments. We agree with the comments regarding other treatment options for polypoidal choroidal vasculopathy (PCV). PDT may be considered alone or in combination with anti-vascular endothelial growth factor (VEGF) drugs. However, anti-VEGF drugs alone also have a significant effect on visual improvement as shown in various studies. As mentioned by the authors, we agree that closure of polyps is an important long-term outcome. In our study, we reported 6 months' results of anti-VEGF monotherapy. Further studies investigating long-term outcome are warranted.